In contrast, for patients whose tumours had a high baseline Ki67 in the POAI group, 73% had a low Ki672w 2 weeks after starting treatment; those patients had a better prognosis at 5 years than those who continued to have a high Ki672W (8·4% vs 21·5% 5-year recurrence risk). This evidence concerns the gene MKI67 and neoplasm.